Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-01-30 1:28 pm Sale | 2025-12-31 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | The Vanguard Group | 1,869,266 4.520% | -160,265 (-7.90%) | Filing History |
| 2026-01-21 12:30 pm Purchase | 2025-12-31 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | BlackRock Inc. BLK | 2,319,341 5.600% | 312,003 (+15.54%) | Filing History |
| 2025-11-14 4:46 pm Sale | 2025-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | Octagon Capital Advisors LP | 1,971,054 4.900% | -5,333 (-0.27%) | Filing History |
| 2025-11-05 11:26 am Purchase | 2025-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | FMR LLC | 3,407,549 8.400% | 1,287,854 (+60.76%) | Filing History |
| 2025-10-30 2:04 pm Purchase | 2025-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | The Vanguard Group | 2,029,531 5.000% | 2,029,531 (New Position) | Filing History |
| 2025-10-17 6:05 pm Purchase | 2025-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | BlackRock Inc. BLK | 2,007,338 4.900% | 75,919 (+3.93%) | Filing History |
| 2025-10-15 4:07 pm Purchase | 2025-10-08 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | HBM Healthcare Investments (Cayman) Ltd. | 2,195,014 5.400% | 2,195,014 (New Position) | Filing History |
| 2025-08-14 4:59 pm Purchase | 2025-06-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | Novo Holdings A/S | 1,872,142 4.900% | 122,142 (+6.98%) | Filing History |
| 2025-08-13 7:43 pm Unchanged | 2025-08-11 | 13D | ArriVent BioPharma, Inc. Common Stock AVBP | ORBIMED ADVISORS LLC | 3,027,328 7.500% | 0 (Unchanged) | Filing History |
| 2025-08-13 7:29 pm Purchase | 2025-06-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | SUVRETTA CAPITAL MANAGEMENT LLC | 3,412,788 9.900% | 1,372,423 (+67.26%) | Filing History |
| 2025-08-13 6:00 pm Purchase | 2025-05-01 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | INFINITUM ASSET MANAGEMENT LLC | 3,418,923 9.900% | 1,352,685 (+65.47%) | Filing History |
| 2025-05-15 4:36 pm Purchase | 2025-05-01 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | INFINITUM ASSET MANAGEMENT LLC | 2,066,238 6.100% | 2,066,238 (New Position) | Filing History |
| 2025-02-14 9:00 pm Purchase | 2025-02-07 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | Novo Holdings A/S | 1,750,000 5.200% | 1,750,000 (New Position) | Filing History |
| 2024-12-04 4:32 pm Purchase | 2024-11-26 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | SUVRETTA CAPITAL MANAGEMENT LLC | 2,040,365 6.100% | 2,040,365 (New Position) | Filing History |
| 2024-11-14 4:33 pm Purchase | 2024-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | HHLR ADVISORS LTD. | 4,484,672 13.400% | 4,484,672 (New Position) | Filing History |
| 2024-11-12 2:45 pm Purchase | 2024-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 1,696,752 5.100% | 1,696,752 (New Position) | Filing History |
| 2024-11-12 09:50 am Purchase | 2024-11-08 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | FMR LLC | 2,119,695 6.311% | 2,119,695 (New Position) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | BlackRock Inc. BLK | 1,931,419 5.800% | 0 (Unchanged) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | BlackRock Inc. BLK | 1,931,419 5.800% | 1,931,419 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | Octagon Capital Advisors LP | 1,976,387 5.900% | 1,976,387 (New Position) | Filing History |